With the ongoing emergence of promising evidence regarding the efficacy of SGLT2 inhibitors and GLP-1RAs in addressing a range of cardiometabolic disorders, the field of sleep medicine may be on the brink of a significant transformation in the management of OSA—especially in individuals with coexisting overweight or obesity. Here, SLC5A2 is linked to Obesity.